Radius Health Inc. (RDUS)

28.34
NASDAQ : Health Technology
Prev Close 28.51
Day Low/High 27.91 / 29.68
52 Wk Low/High 12.81 / 29.44
Avg Volume 483.90K
Exchange NASDAQ
Shares Outstanding 46.12M
Market Cap 1.31B
EPS -4.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
Radius Presents Analysis Results On Fracture Risk Reduction In Phase 3 ACTIVE Trial For Investigational Drug Abaloparatide-SC At The ENDO 2016 Annual Meeting

Radius Presents Analysis Results On Fracture Risk Reduction In Phase 3 ACTIVE Trial For Investigational Drug Abaloparatide-SC At The ENDO 2016 Annual Meeting

- Data demonstrate that abaloparatide-SC reduced the risk of osteoporotic fractures and increased bone mineral density across a broad group of postmenopausal women with osteoporosis regardless of baseline characteristics -

Jim Cramer's Top Takeaways: Radius Health, Seres Therapeutics

Jim Cramer's Top Takeaways: Radius Health, Seres Therapeutics

Radius Health and Seres Therapeutics have something in common, Cramer says -- both are great biotechs being dragged down by the current market.

Jim Cramer's 'Mad Money' Recap: Good Riddance to a Roller-Coaster Quarter

Jim Cramer's 'Mad Money' Recap: Good Riddance to a Roller-Coaster Quarter

When it comes to the first quarter of 2016, it was the worst of times or it was the best of times, Cramer says

'Mad Money' Lightning Round: I'm a Palo Alto Networks Guy

'Mad Money' Lightning Round: I'm a Palo Alto Networks Guy

Cramer loves Bristol-Myers and he's not betting against Goldman Sachs.

Jim Cramer's 'Mad Money' Recap: Buy These Winners When the Smoke Clears

Jim Cramer's 'Mad Money' Recap: Buy These Winners When the Smoke Clears

There are many low-value stocks that never should've gotten that low in the first place, Cramer says.

Radius Health (RDUS) Stock Price Target Cut at Cantor Fitzgerald

Radius Health (RDUS) Stock Price Target Cut at Cantor Fitzgerald

Cantor Fitzgerald lowered its price target on Radius Health (RDUS) stock to reflect lower biotechnology valuations in the current market environment.

Radius Health (RDUS) Stock Falls as Jefferies Cuts to 'Hold'

Radius Health (RDUS) Stock Falls as Jefferies Cuts to 'Hold'

Radius Health (RDUS) stock is lower in pre-market trading on a ratings downgrade to 'hold' from 'buy' at Jefferies.

Analysts' Actions -- Ford, Macy's, AT&T, Walmart and More

Analysts' Actions -- Ford, Macy's, AT&T, Walmart and More

Here are Wednesday's top research calls, including downgrades for Ford and Macy's, an upgrade for Walmart and new coverage on AT&T.

Here's Why Radius Health (RDUS) Stock Skyrocketed Today

Here's Why Radius Health (RDUS) Stock Skyrocketed Today

Radius Health (RDUS) stock closed up today after Amgen (AMGN) reported data indicating that its osteoporosis drug didn't perform as well as Radius Health's.

Amgen Osteoporosis Drug Lowers Spine Fracture Risk in Key Study

Amgen Osteoporosis Drug Lowers Spine Fracture Risk in Key Study

Amgen and partner UCB intend to seek regulatory approval for the new osteoporosis drug, romosozumab, later this year.

Radius Health Is Still on the Defensive

Shares of the biopharmaceutical company appear no closer to a bottom. 

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan

Cramer is watching earnings in a week that should continue to be dominated by oil, China and the Federal Reserve.

'Mad Money' Lightning Round: Hold Altria for the Long Term

'Mad Money' Lightning Round: Hold Altria for the Long Term

Cramer is avoiding 3D Systems and prefers Nordic American Tanker over Teekay Shipping.

'Mad Money' Lightning Round: Take a Long-Term View on Radius Health

'Mad Money' Lightning Round: Take a Long-Term View on Radius Health

Cramer is ready to buy American International Group as it comes down but is not a buyer of CIT Group.

Jim Cramer's 'Mad Money' Recap: New Rules for a Tanking Market

Jim Cramer's 'Mad Money' Recap: New Rules for a Tanking Market

The selling isn't over yet, Cramer warned.

Jim Cramer's 'Mad Money' Recap: The Sellers Have Left the Building

Jim Cramer's 'Mad Money' Recap: The Sellers Have Left the Building

Every year brings new optimism, but for much of the market things are still terrible, Cramer says.

'Mad Money' Lightning Round: Avoid Staples and Transocean

'Mad Money' Lightning Round: Avoid Staples and Transocean

Cramer wants you to buy Wells Fargo, isn't riding Canadian Pacific Railway and likes T-Mobile over Sprint.

Jim Cramer's 'Mad Money' Recap: Brace Yourself for the Fed

Jim Cramer's 'Mad Money' Recap: Brace Yourself for the Fed

Today's market signaled that most investors feel there will only be one coming interest rate hike, but that might not be the case tomorrow.

TheStreet Quant Rating: D- (Sell)